文献速递心境障碍物质与行为成瘾

代谢型谷氨酸受体5作为抑郁症与吸烟治疗靶点:临床前数据强劲但临床疗效未定

Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.
PubMed 文献 · Biol Psychiatry · 2018-03-09

该综述聚焦代谢型谷氨酸受体5(mGlu5)在重性抑郁障碍与物质/酒精使用障碍中的潜在作用,梳理了靶向mGlu5的临床前证据与近期临床试验结果。临床前研究显示负向调节mGlu5有希望,但有益效应未转化为临床疗效;作者分析了转化瓶颈的挑战并提出改进方向。

要点

  • 临床前证据支持负向调节mGlu5治疗重性抑郁障碍与尼古丁依赖,但临床疗效未获证实。
  • 精神疾病缺乏生物学边界,临床前到临床的转化瓶颈是药物研发的重要挑战。
  • 作者提出改进转化研究的方法,以可能提高临床试验成功率并缩小转化瓶颈。

核心结论

  • mGlu5负向变构调节在临床前研究中显示希望,但有益效应未转化为临床疗效。

研究设计与样本

  • 综述聚焦mGlu5受体在重性抑郁障碍与物质和/或酒精使用障碍中的潜在参与。
  • 文章概述靶向mGlu5的理由,总结临床前证据并强调近期临床试验结果。

主要发现

  • 谷氨酸传递在多种神经精神障碍中被打断,mGlu受体参与兴奋性神经传递。
  • mGlu5表达广泛但具区域特异性,为微妙而选择性调节兴奋性传递提供机会。
  • 临床前研究支持负向调节mGlu5作为重性抑郁障碍与尼古丁依赖的治疗靶点。

临床怎么用

  • 作者建议采取特定方法以可能改善临床前到临床领域的转化。
  • 这些方法可能提高临床试验成功率并减少精神疾病药物发现中的转化瓶颈。

局限性

  • 临床前有益效应未转化为临床疗效,提示存在转化瓶颈。
  • 作者识别了可能导致临床转化不佳的关键挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ability of novel pharmacological compounds to improve outcomes in preclinical models is often not translated into clinical efficacy. Psychiatric disorders do not have biological boundaries, and identifying mechanisms to improve the translational bottleneck between preclinical and clinical research domains is an important and challenging task. Glutamate transmission is disrupted in several neuropsychiatric disorders. Metabotropic glutamate (mGlu) receptors represent a diverse class of receptors that contribute to excitatory neurotransmission. Given the wide, yet region-specific manner of expression, developing pharmacological compounds to modulate mGlu receptor activity provides an opportunity to subtly and selectively modulate excitatory neurotransmission. This review focuses on the potential involvement of mGlu5 receptor disruption in major depressive disorder and substance and/or alcohol use disorders. We provide an overview of the justification of targeting mGlu5 receptors in the treatment of these disorders, summarize the preclinical evidence for negatively modulating mGlu5 receptors as a therapeutic target for major depressive disorders and nicotine dependence, and highlight the outcomes of recent clinical trials. While the evidence of mGlu5 receptor negative allosteric modulation has been promising in preclinical investigations, these beneficial effects have not translated into clinical efficacy. In this review, we identify key challenges that may contribute to poor clinical translation and provide suggested approaches moving forward to potentially improve the translation from preclinical to clinical domains. Such approaches may increase the success of clinical trials and may reduce the translational bottleneck that exists in drug discovery for psychiatric disorders.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Barnes SA, Sheffler DJ, Semenova S, et al. Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy. Biol Psychiatry. 2018. PMID: 29628194. doi:10.1016/j.biopsych.2018.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。